The US Food and Drug Administration (FDA) Approves the Lu-177-PSMA Radiopharmaceutical

The Lu-177-PSMA radiopharmaceutical, which is used to treat patients with metastatic prostate cancer, is approved by the US Food and Drug Administration (FDA). This radiopharmaceutical is produced in Pars Isotope under the brand name of PARS-Luto PSMA to be sent to the medical centers on request.

The FDA is responsible for protecting and promoting public health through the regulation, control and supervision of food safety, medications and cosmetics. FDA approval is an international certification issued by the Food and Drug Administration to manufacturers of food, pharmaceutical and health products worldwide. Given that the FDA name and its role in providing standards related to food and pharmaceutical products are known to all in all countries, obtaining this approval can play a significant role in attracting domestic and foreign customers for the sale and export. Also, it should be noted that FDA approval is granted after various clinical trials.

Due to the growing interest in nuclear medicine methods for the diagnosis and treatment of various types of disease and cancer, obtaining international approvals can spotlight the use of radiopharmaceuticals, significantly. The Lu-177-PSMA radiopharmaceutical is also a definitive treatment for patients whose cancer cells have spread from the prostate to the bones or throughout the body. The usefulness of this radiopharmaceutical product in the treatment of this disease has been proven many times.